Vera Therapeutics Earnings Estimate

VERA Stock  USD 29.93  0.52  1.77%   
The next projected EPS of Vera Therapeutics is estimated to be -0.76 with future projections ranging from a low of -0.76 to a high of -0.76. Vera Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at -2.75. Please be aware that the consensus of earnings estimates for Vera Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
Vera Therapeutics is projected to generate -0.76 in earnings per share on the 31st of March 2025. Vera Therapeutics earnings estimates show analyst consensus about projected Vera Therapeutics EPS (Earning Per Share). It derives the highest and the lowest estimates based on Vera Therapeutics' historical volatility. Many public companies, such as Vera Therapeutics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Vera Therapeutics' earnings estimates, investors can diagnose different trends across Vera Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes. The current year's Gross Profit is expected to grow to about 2.2 M, whereas Pretax Profit Margin is forecasted to decline to (48.72).
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vera Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Vera Stock refer to our How to Trade Vera Stock guide.

Vera Therapeutics Earnings Estimation Breakdown

The calculation of Vera Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Vera Therapeutics is estimated to be -0.76 with the future projection ranging from a low of -0.76 to a high of -0.76. Please be aware that this consensus of annual earnings estimates for Vera Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
-0.72
-0.76
Lowest
Expected EPS
-0.76
-0.76
Highest

Vera Therapeutics Earnings Projection Consensus

Suppose the current estimates of Vera Therapeutics' value are higher than the current market price of the Vera Therapeutics stock. In this case, investors may conclude that Vera Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Vera Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of March 2025Current EPS (TTM)
1380.62%
-0.72
-0.76
-2.75

Vera Therapeutics Earnings History

Earnings estimate consensus by Vera Therapeutics analysts from Wall Street is used by the market to judge Vera Therapeutics' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Vera Therapeutics' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.

Vera Therapeutics Quarterly Gross Profit

952,000

The current year's Retained Earnings is expected to grow to about (264.3 M). In addition to that, Retained Earnings Total Equity is expected to decline to about (201.4 M) The current year's Common Stock Shares Outstanding is expected to grow to about 51.6 M. The current year's Net Income Applicable To Common Shares is expected to grow to about 107.5 M.
Hype
Prediction
LowEstimatedHigh
26.1129.9833.85
Details
Intrinsic
Valuation
LowRealHigh
26.9437.4041.27
Details
12 Analysts
Consensus
LowTargetHigh
58.7764.5871.69
Details
Note that many institutional investors and large investment bankers can move markets due to the volume of Vera assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards Vera Therapeutics. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving Vera Therapeutics' stock price in the short term.

Vera Therapeutics Earnings per Share Projection vs Actual

Actual Earning per Share of Vera Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Vera Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Vera Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Vera Therapeutics Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Vera Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Vera Therapeutics should always be considered in relation to other companies to make a more educated investment decision.

Vera Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Vera Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-12-31
2024-12-31-0.73-0.720.01
2024-11-07
2024-09-30-0.6184-0.85-0.231637 
2024-08-08
2024-06-30-0.56-0.62-0.0610 
2024-05-09
2024-03-31-0.53-0.56-0.03
2024-03-20
2023-12-31-0.51-0.6-0.0917 
2023-11-09
2023-09-30-0.53-0.450.0815 
2023-08-10
2023-06-30-0.69-0.460.2333 
2023-05-11
2023-03-31-0.6-0.8-0.233 
2023-03-28
2022-12-31-0.9-1.18-0.2831 
2022-11-09
2022-09-30-0.72-0.91-0.1926 
2022-08-10
2022-06-30-0.72-0.550.1723 
2022-05-16
2022-03-31-0.67-0.71-0.04
2022-03-24
2021-12-31-0.46-0.79-0.3371 
2021-11-10
2021-09-30-0.59-0.360.2338 
2021-08-16
2021-06-30-0.39-0.330.0615 
2021-06-24
2021-03-31-1.94-12.23-10.29530 

About Vera Therapeutics Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Vera Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Vera Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Vera Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-278.2 M-264.3 M
Retained Earnings Total Equity-191.8 M-201.4 M
Earnings Yield(0.07)(0.07)
Price Earnings Ratio(15.38)(16.15)
Price Earnings To Growth Ratio(0.69)(0.66)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Vera Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vera Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vera Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vera Therapeutics Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vera Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Vera Stock refer to our How to Trade Vera Stock guide.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vera Therapeutics. If investors know Vera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vera Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.75)
Return On Assets
(0.25)
Return On Equity
(0.45)
The market value of Vera Therapeutics is measured differently than its book value, which is the value of Vera that is recorded on the company's balance sheet. Investors also form their own opinion of Vera Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vera Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vera Therapeutics' market value can be influenced by many factors that don't directly affect Vera Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vera Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vera Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vera Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.